Target intelligence / Profile preview

Immunoglobulin iota chain (VPREB1)

Target
VPREB1
Molecular classification
Immunoglobulin superfamily, Pseudo (surrogate) light chain component, Pre-B cell receptor complex protein, Cell surface receptor component
01

Overview

Immunoglobulin iota chain (VPREB1) is a 126-amino acid protein (16-18 kDa), encoded by the VPREB1 gene on chromosome 22. It is expressed selectively during the early stages of B cell development (pro-B and early pre-B cells), where it forms a non-covalent complex with CD179b (lambda5), known as the surrogate (or pseudo) light chain. Together, VPREB1 and CD179b associate with the Ig mu heavy chain and signal transducers (CD79a/CD79b) to produce the pre-B cell receptor (preBCR), essential for B lymphocyte maturation. This receptor complex regulates immunoglobulin gene rearrangement, allelic exclusion at the Ig heavy chain locus, and promotes Ig light chain gene rearrangements, acting as a functional checkpoint in B cell development. No human diseases are directly linked exclusively to VPREB1 mutations or dysfunction, but deficiencies in associated components result in severe impairment of B cell development, leading to immunodeficiencies such as agammaglobulinemia. VPREB1 is considered a diagnostic marker in some forms of leukemia and immune disorders, though it is not currently a direct therapeutic drug target[1][3][4][5][8].

Other names
V-set pre-B cell surrogate light chain 1VPREBCD179aImmunoglobulin iota chainCD179 antigen-like family member AProtein VPreB1pre-B lymphocyte 1IGIIGVPBCD179A
02

Biological functions

Regulation of immunoglobulin gene rearrangementsImmune responseB cell developmentSignal transductionQuality control checkpoint for immunoglobulin heavy chain expression
03

Disease associations

Immunodeficiency (including mu chain disease, lambda 5 deficiency, combined immunodeficiency)Possibly cancer (B-cell precursor acute lymphoblastic leukemia prognosis)Other (associated with various immunodeficiencies and rare disorders)
04

Safety considerations

No specific safety concerns or therapeutic challenges directly reported for targeting VPREB1; impairing related pathways could impact B cell development and immune function
05

Biomarkers

Potential prognostic marker in pediatric B-cell precursor acute lymphoblastic leukemia (high expression may correlate with good prognosis)

Beyond the preview

Go deeper on Immunoglobulin iota chain (VPREB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin iota chain (VPREB1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call